CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress [Yahoo! Finance]
CytomX Therapeutics, Inc. (CTMX)
Last cytomx therapeutics, inc. earnings: 11/7 04:09 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytomx.com
Company Research
Source: Yahoo! Finance
reiterated their Buy rating on CytomX Therapeutics (NASDAQ:CTMX) and set a $16 price target. The research firm remains bullish on the company following topline results from its candidate drug, Varseta-M. CytomX Therapeutics, Inc. (CTMX) A Top Healthcare Penny Stock Amid Colorectal Cancer Treatment Progress Varseta-M is a first-in-class antibody-drug conjugate targeting the epithelial cell adhesion molecule in colorectal cancer. Trials' results for the candidate drug showed no EpCAM-class toxicities in an expanded dataset of approximately 80 patients. Nevertheless, management confirmed they are working to address the diarrhea adverse event migration and dose fine-tuning. CytomX Therapeutics has already conducted a $250 million public offering as it seeks to secure the much-needed capital to accelerate the development of its candidate drugs. On the other hand, Jefferies has identified incremental efficacy and durability updates for the candidate drug to bolster the stock's market
Show less
Read more
Impact Snapshot
Event Time:
CTMX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CTMX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CTMX alerts
High impacting CytomX Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CTMX
News
- CytomX Therapeutics (CTMX) Making Progress on Key Metastatic Colorectal Cancer Treatment [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics (CTMX) Gains Analyst Confidence on Trial Progress [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics (CTMX) had its price target raised by Piper Sandler from $10.00 to $12.00. They now have an "overweight" rating on the stock.MarketBeat
- A Look At CytomX Therapeutics (CTMX) Valuation After Positive Varsetatug Masetecan Phase 1 Expansion Results [Yahoo! Finance]Yahoo! Finance
- CytomX Therapeutics (CTMX) was downgraded by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from "hold (c-)" to "sell (d)".MarketBeat
CTMX
Earnings
- 3/16/26 - Miss
CTMX
Sec Filings
- 4/16/26 - Form SCHEDULE
- 3/26/26 - Form SCHEDULE
- 3/19/26 - Form 4
- CTMX's page on the SEC website